IMAB

I-Mab

Add to Watchlist

Advanced Chart

3.650

-0.04(-1.084%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.810

Open

3.690

VWAP

3.68

Vol

1.62M

Mkt Cap

420.19M

Low

3.520

Amount

5.96M

EV/EBITDA(TTM)

Total Shares

80.88M

259.18M

EV/OCF(TTM)

P/S(TTM)

I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.046

-58.18%

-0.048

-4%

-0.030

-25%

Estimates Revision

The market is revising No Change the revenue expectations for I-Mab (IMAB) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 56.65%.

EPS Estimates for FY2025

Revise Upward

+15.55%

In Past 3 Month

Stock Price

Go Up

+56.65%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast IMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMAB is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.650

Low

6.00

Averages

7.00

High

8.00

Current: 3.650

Low

6.00

Averages

7.00

High

8.00

BTIG

Justin Zelin

Buy

maintain

2025-09-10

Reason

BTIG

Justin Zelin

Price Target

2025-09-10

maintain

Buy

Reason

BTIG analyst Justin Zelin notes that I-Mab shares have fallen about 20% following a New York Times article highlighting the Trump administration's potential consideration of restrictions on Chinese produced medicines under CFIUS review, but the firm believes the market is \"misinterpreting the situation as applying to I-Mab\" and views the selloff as \"an unwarranted mispricing and not a fundamental risk.\" The firm, which reminds investors that I-Mab is not a Chinese drugmaker, but a U.S.-based biotech company and that it has no China licensing risk for givastomig, calls the weakness \"an overreaction to a mischaracterization\" and would be buyers amid the weakness. BTIG reiterates a Buy rating and $7 price target on I-Mab shares.

BTIG

Buy

initiated

2025-09-09

Reason

BTIG

Price Target

2025-09-09

initiated

Buy

Reason

BTIG initiated coverage of I-Mab with a Buy rating and $7 price target. The firm believes givastomig has \"best-in-class potential\" to redefine first-line gastric cancer treatment. Unlike Zolbetuximab, givastomig's 10-times more potent conditional 4-1BB design drives activity across CLDN18.2-low and PD-L1-low populations, which doubles the addressable market, the analyst tells investors in a research note. BTIG believes the drug's early durability and \"clean\" safety profile validate its \"differentiated mechanism.\" It sees a near-term catalyst for I-Mab shares with a Q1 of 2026 data release.

Needham

Buy

maintain

$5 -> $6

2025-08-20

Reason

Needham

Price Target

$5 -> $6

2025-08-20

maintain

Buy

Reason

Needham raised the firm's price target on I-Mab to $6 from $5 and keeps a Buy rating on the shares. Givastomig dose expansion results remain on track for 1Q26 and will help determine next steps for the program, the analyst tells investors in a research note. The firm also believes recent financing removes a potential overhang from the stock and raised its price target to reflect increased value for givastomig.

Lucid Capital

initiated

2025-05-28

Reason

Lucid Capital

Price Target

2025-05-28

initiated

Reason

Lucid Capital initiated coverage of I-Mab with a Buy rating and $5 price target. I-Mab is a clinical-stage biotechnology company focused on precision therapeutics for the treatment of cancer, the analyst tells investors in a research note. The firm believes the company's CLDN18.2 x 4-1BB bispecific antibody, givastomig, could be a significant value driver for shares, approaching the top-line Phase 1b combination dose escalation and dose expansion data.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Maintains

$8 → $7

2025-04-04

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$8 → $7

2025-04-04

Maintains

Strong Buy

Reason

Needham

Gil Blum

Strong Buy

Reiterates

2025-04-04

Reason

Needham

Gil Blum

Price Target

2025-04-04

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for I-Mab (IMAB.O) is -23.70, compared to its 5-year average forward P/E of -15.79. For a more detailed relative valuation and DCF analysis to assess I-Mab 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-15.79

Current PE

-23.70

Overvalued PE

7.05

Undervalued PE

-38.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.20

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

27.26

Undervalued EV/EBITDA

-37.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

14.11

Current PS

0.00

Overvalued PS

49.51

Undervalued PS

-21.29